COSMO Pharmaceuticals SA operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares COSMO Pharmaceuticals SA with three other
pharmaceutical manufacturers in Europe:
Solon Eiendom ASA
sales of 691.50 million Norwegian Kroner [US$83.30 million]
of which 114%
was Residential Real Estate),
(277.61 million Polish New Zlotys [US$77.76 million]
of which 60%
was Insulin (Bioton SA)), and
Bosnalijek d.d. Sarajevo
based in Bosnia
(135.81 million Bosnian Convertible Marks [US$81.82 million]
COSMO Pharmaceuticals SA reported sales of 67.66 million Euro (US$79.60 million)
December of 2016.
increase of 11.6%
versus 2015, when the company's sales were 60.61 million Euro.
Despite this increase, sales are still
below the level achieved in 2014, when COSMO Pharmaceuticals SA
reported sales of 79.59 million Euro.
Sales of Other Revenues From Sale saw an increase
that was more than double the company's growth rate: sales were up
369.4% in 2016, from
196,000.00 Euro to 920,000.00 Euro.
COSMO Pharmaceuticals SA also saw significant increases in sales in
Manufacturing of Mmx Products (up 23.5% to 35.87 million Euro)
Royalties (up 58.8% to 20.21 million Euro)
Related Services (up 18.2% to 1.07 million Euro)
Not all segments of COSMO Pharmaceuticals SA experienced an increase in sales in 2016:
sales of License Fees and Milestones fell 94.4% to 445,000.00 Euro.
COSMO Pharmaceuticals SA also experienced decreases in sales in
Manufacturing of Generic Products and Sp (down 6.0% to 9.15 million Euro)